Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Thymoma 1Sarcoma, Synovial 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Meningioma 1Medulloblastoma 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Everolimus 8lanreotide 3gallium Ga 68 dotatate 3Octreotide 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1ganitumab 1fosbretabulin 1epothilone B 1cixutumumab 1arginyllysine 1TKM-080301 1Sorafenib 1Serotonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × olaparib × NET × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡